Fig. 4: Subgroup analysis of OS by CAR-T therapy in R/R B-ALL patients (statistically significant). | Cell Death & Disease

Fig. 4: Subgroup analysis of OS by CAR-T therapy in R/R B-ALL patients (statistically significant).

From: Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients

Fig. 4

OS was longer in patients with non-refractory disease compared with patients with refractory disease (a), patients with other lymphodepletion regimens compared with patients with Flu + Cy regimen (b) and in patients with bridging to HSCT compared with patients with CAR-T therapy only (c). Kaplan–Meier curve was used to demonstrate survival profiles, and the log-rank test was used to determine the difference between paired subgroups. P < 0.05 was considered significant. OS, overall survival; Flu + Cy, cyclophosphamide plus fludarabine; HSCT, hematopoietic stem-cell transplantation; CAR-T, chimeric antigen-specific T cell.

Back to article page